Feedback Plc (LON: FDBK) have updated shareholders about a new trial with Pennine Acute Hospitals NHS for its new medical communication platform, Bleepa.
Shares of Feedback plc (LON: FDBK) are trading at 1p. 18/11/19 14:34BST.
In the medical and pharmaceuticals sector, the big names have continued to dominate headlines. Pfizer (NYSE: PFE) have smashed analyst and market expectations.
Additionally, British rival GSK (LON: GSK) raised their annual profit forecast following a strong quarterly update.
Bleepa is a platform which enables clinicians to access medical grade images through smartphones, tablets and desktop computers.
Shareholders can be optimistic, as it seems that the NHS have bought into the Bleepa software after agreeing a trial deal.
Feedback added that the trial is set to go live in December, and last for approximately three months to allow a full review of the system.
Seniority at Feedback anticipated that the pilot will be extended to include other clinical teams within the Trust, and expects diversification into the Orthopaedic and Vascular sector.
Dr Tom Oakley, CEO of Feedback, commented:
“Pennine Acute Hospitals NHS Trust is a renowned adopter of new technology given its status as a GDE Fast follower site, and we look forward to working with the team on our first pilot study of Bleepa®. We believe that Bleepa will accelerate the process of requesting a specialist opinion from colleagues, ultimately resulting in better care for patients, faster.
“The Pennine Acute Hospitals NHS Trust pilot study is our first, but with the interest we have received since the launch of Bleepa at the NHS Expo 2019 in September, we anticipate more to follow.”
Libby Woodcock, EPR Transformation Manager of Pennine Acute Hospitals NHS Trust, commented:
“Transforming clinical services by providing digital enablement is always high on our agenda and we are excited to be involved.”
Dr Georges Ng Man Kwong, Consultant Chest Physician and CCIO of Pennine Acute Hospitals NHS Trust, commented:
“Bleepa is addressing a direct clinical challenge to better support our busy respiratory clinicians (at the Royal Oldham Hospital) by improving referral process and patient care. Each referral requires rapid and reliable access to radiology images and clinical handover information, and a means of messaging referring teams and documenting outcome. Bleepa has the potential to bring this together for our clinicians and therefore for our patients. We are delighted to be involved with this innovation solution.”
This morning in the medical sector, it was also reported that Consort Medical (LON: CSRT) had merged with Swedish based Recipharm (STO: RECI-B).
Feedback have also said the strategic review for its TexRAD medical image analysis technology has needed further developments to support a US Food & Drug Administration submission.
“We have made some product modifications to TexRAD Research in response to customer feedback and are evaluating the impact of these on revenue. In the near term, we will continue to sell TexRAD within the research setting through third party distributors which provides a more cost-effective avenue for maintaining our sales efforts. As a result, we have reduced the resources associated with TexRAD,” said Oakley.
